MINK THERAPEUTICS INC

Biotech · Public

agenT-797, an off-the-shelf allogeneic cellular immunotherapy composed of invariant Natural Killer T (iNKT) cells for hematopoietic stem cell transplantation

Grants
$613K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
30
4 granted · 26 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications$306,500
Federal grantDepartment of Health and Human Services · Phase I · Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications$306,500
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1630Atum Works——
1631Quell Therapeutics——
1632Inipharm——
1633MINK THERAPEUTICS INC——
1634MANHATTAN BIOSOLUTIONS, LLC——
1635Find Genomics Inc.——
1636Amplifier Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 30

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.